Erythropoietin Therapy for Children With Cerebral Palsy
NCT ID: NCT01650415
Last Updated: 2017-10-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
11 participants
INTERVENTIONAL
2014-09-30
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Many experimental animal studies have revealed that erythropoietin is useful to repair neurological injury in brain. The main mechanism of erythropoietin is supposed as follows;
1. Neuroprotection effect
2. Angiogenesis
3. Anti-inflammation.
On the basis of many experimental studies, erythropoietin is suggested as a therapeutic method for cerebral palsy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Erythropoietin and Rehabilitation
recombinant human erythropoietin injection and active rehabilitation
Erythropoietin
twice a week for 1 month
Placebo and Rehabilitation
Placebo erythropoietin and rehabilitation
Placebo erythropoietin
twice a week for 1 month
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erythropoietin
twice a week for 1 month
Placebo erythropoietin
twice a week for 1 month
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Abnormal Muscle Tone
* Abnormal Brain MRI
* Willing to Comply with All Study Procedure
Exclusion Criteria
* Other Etiologies Contributing Developmental Delay
* Coagulopathy
* Initial high Erythropoietin level in Serum
* Previous Erythropoietin Treatment before 3 months
* Presence of Drug Hypersensitivity Related to the Study Remedy
* Intractable Seizure Disorder
* Poor Cooperation of Guardian including Inactive Attitude for Rehabilitation
4 Months
4 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LG Life Sciences
INDUSTRY
Bundang CHA Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MinYoung Kim, M.D.
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Minyoung Kim, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
CHA University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHA Bundang Medical Center, CHA University
Seongnam-si, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CPEPO
Identifier Type: -
Identifier Source: org_study_id